Demonstrates enhanced lung-specific delivery and efficacy of paclitaxel liposomes in lung cancer therapy, suggesting improved treatments for pulmonary carcinoma.
Successful chemotherapy of pulmonary carcinoma requires both efficient lung accumulation and controlled intracellular drug release. Here, we developed a lung-tropic redox-responsive paclitaxel liposome (Lu-rePTX/Lipo) by co-assembling the cationic lipid DOTAP, a disulfide-linked phospholipid–paclitaxel conjugate (GPCssPTX), and DSPE-PEG2000. The optimized formulation showed a particle size below 200 nm, favorable lung accumulation, and glutathione-triggered PTX release. Increased DOTAP incorporation enhanced lung tropism and promoted PTX accumulation in lung tissue. Lu-rePTX/Lipo also exhibited enhanced cellular uptake and stronger cytotoxicity against LLC1 cells, while maintaining reduced toxicity toward normal cells due to redox-selective drug release. In an LLC1-bearing mouse model, Lu-rePTX/Lipo achieved superior antitumor efficacy compared with control formulations. These results demonstrate that integrating DOTAP-mediated lung tropism with a redox-responsive phospholipid prodrug strategy provides a promising platform for pulmonary carcinoma therapy.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: